NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy (NCT04112641)

🧪 Interventions in This Study

• Nicotinamide riboside (DRUG)
• Placebo capsules (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Be able to give written informed consent and HIPAA authorization
2. Be ≥ 18 and ≤ 85 years of age
3. Have received chemotherapy with taxane (e.g. paclitaxel, nab-paclitaxel, or docetaxol) or platinum-complex (e.g. oxaliplatin, carboplatin, or cisplatin) (alone or in combination) and completed therapy no sooner than 1 month and no later than 1 year earlier.
4. Have been treated with above compounds for head and neck cancer, small cell lung cancer, sarcoma, ovarian cancer, endometrial cancer, colorectal cancer, or breast cancer and been declared to have no visible evidence of disease.
5. Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
6. Able to take medication orally - up to four capsules in the morning (am) and four capsules in the evening (pm).
7. Be determined to have a raw score of ≥ 12 on the sensory subscale or ≥ 11 on the motor subscale of the QLQ-CIPN20 questionnaire.
8. Females must be either postmenopausal for at least 1 year or surgically sterile for at least 6 weeks. Females of childbearing potential must have a negative pregnancy test at screening to be eligible for study participation and agree to take appropriate precautions to avoid pregnancy from screening through follow-up.
9. Males must agree to take appropriate precautions to avoid fathering a child from screening through follow-up. The following methods have been determined to be more than 99% effective (\<1% failure rate per year when used consistently and correctly) \[69\] and are permitted under this protocol for use by the patient and his/her partner:
10. Complete abstinence from sexual intercourse when this is in line with the preferred and usual lifestyle of the patient
11. Double barrier methods
12. Condom with spermicide in conjunction with use of an intrauterine device

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

• Donna Hammond — Iowa City, Iowa

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Chemotherapy-induced Peripheral Neuropathy

• Neural and Immune Correlates of CIPN and Possible Analgesic Effect of Non-invasive Motor Cortex Stimulation — Baltimore, Maryland
• The Effect of Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy) — Boston, Massachusetts
• Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy — Houston, Texas
• CBG/CBD Oil for Chemotherapy-Induced Peripheral Neuropathy — Hershey, Pennsylvania
• A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors Post-treatment — Ann Arbor, Michigan

Explore by condition: All Chemotherapy-induced Peripheral Neuropathy clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.